Compare Amylx Pharmaceuticals Inc (AMLX) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Deckers Outdoor Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Deckers Outdoor Corp trades at $107.5 (market cap $14.72B). The key difference: Deckers Outdoor Corp is far larger — about 7.4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| AMLX | DECK | |
|---|---|---|
Market Cap | $1.98B | $14.72B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $123.91 |
52-Week Low | $7.64 | $79.54 |
Enterprise Value | $1.70B | $13.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
DECK trades at $105.99, up 1.66% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.99B in 2025, with net income reaching $966M and profit margin expanding to 19.37%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.96 versus $0.83 expected. Cash flow from operations remains robust at $1.04B, supporting financial stability.
The stock offers upside to the $121.50 consensus price target, driven by HOKA and UGG global growth. Risks include competitive pressures and volatile technical indicators. Analyst sentiment is mixed with 41.82% buy ratings, but institutional holdings suggest long-term confidence amid near-term bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
